Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies

T. H. Han, R. Chen, R. Advani, R. B. Berryman, S. E. Smith, A. Forero-Torres, J. D. Rosenblatt, M. R. Smith, J. Zain, N. N. Hunder, A. Engert

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds